Dequalinium chloride vaginal tablet - Medinova

Drug Profile

Dequalinium chloride vaginal tablet - Medinova

Alternative Names: Fluomizin; Naxyl

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Medinova
  • Developer Medinova; Merck; Pierre Fabre; Vivax Pharmaceuticals
  • Class Antifungals; Antineoplastics; Antiseptics; Quinolines; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers; Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bacterial vaginosis; Vulvovaginal candidiasis

Most Recent Events

  • 13 Sep 2016 Duchesnay announces intention to submit NDA to Health Canada
  • 15 Mar 2016 Biomarkers information updated
  • 15 Sep 2014 Medinova plans a phase IV trial for Vulvovaginal candidiasis in Thailand (NCT02242695)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top